Cerebrovascular diseases and personalized prevention

Tanashyan M.M.; Raskurazhev A.A.; Kornilova A.A.

doi:https://doi.org/10.17116/profmed20212402176

Close metadata

Recommended articles:

Potential for the use of nutraceuticals for hyperlipidemia correction. Russian Journal of Preventive Medicine. 2025;(3):40-45

The place of non-high-density lipoprotein cholesterol and triglycerides in the assessment of cardiovascular risk: Resolution of the Panel of Experts. Russian Journal of Preventive Medicine. 2025;(4):7-15

Neutrophil elastase as a promising biomarker of low-grade inflammation in chronic non-communicable diseases. Russian Journal of Preventive Medicine. 2025;(4):142-148

Potential and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medicine. 2025;(7):94-99

Intercellular adhesion proteins: P-, E-, H-cadherins as oncological and cardiovascular diseases’ biomarkers. Russian Journal of Preventive Medicine. 2025;(7):100-105

Increased expression of circular RNA circSPARC and circTMEM181 in coronary atherosclerosis. Molecular Genetics, Microbiology and Virology. 2025;(1):24-29

The influence of demographic factors and major comorbidities on serum circulating regulatory microRNAs in patients with coronary artery atherosclerosis and thoracic aortic aneurysm: a single-center cohort study. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):174-182

Prevalence and characteristics of risk factors for cerebrovascular disease in overweight. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):118-124

Features of care of patients with cardiovascular diseases and cognitive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):99-104

Comparison of the results of autovenous bypass surgery on the anterior tibial artery depending on access choice. Pirogov Russian Journal of Surgery. 2025;(7):5-10

Abstract:

The mortality rate of the population of the Russian Federation due to cerebrovascular diseases was more than 260 thousand people in 2018. Personalized medicine is potentially capable of improving the management of risk factors for cardiovascular diseases. At the same time, insufficient attention is often paid to the gender characteristics of patients, although women have a higher increase in cardiovascular events with age compared to men. Atherosclerosis and atherosclerotic plaque destabilization are among the most common causes of ischemic thrombotic events. Antiplatelet therapy is the main method of preventing cerebral thrombotic complications; however, the prescription of these drugs in the context of primary prevention is associated with a number of unresolved issues. The article is a literature review highlighting the importance of controlling personified CVD risk factors based on a multidisciplinary approach.

Keywords:

personalized prevention

cerebrovascular disease

atherosclerosis

acetylsalicylic acid

Authors:

Tanashyan M.M.

Research Center of Neurology

Raskurazhev A.A.

Scientific Center of Neurology

Kornilova A.A.

Scientific Center of Neurology

Received:

20.02.2020

Accepted:

09.10.2020

Close metadata

References:

Federal’naya sluzhba gosudarstvennoj statistiki. Smertnost’ naseleniya po prichinam smerti v 2018 godu. M.: Rosstat; 2019. Accessed January 4, 2021. (In Russ.). https://www.gks.ru/free_doc/2018/demo/t3_3.xls
Piradov MA, Maksimova MYu, Tanashyan MM. Insul’t: poshagovaya instrukciya. M.: GEOTAR-Media; 2019. (In Russ.).
Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O’Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C. Global and regional burden of stroke during 1990—2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383(9913):245-254. https://doi.org/10.1016/s0140-6736(13)61953-4
Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics — 2011 update: a report from the American Heart Association. Circulation. 2011;123(4):18-209. https://doi.org/10.1161/CIR.0b013e3182009701
Schleidgen S, Klingler C, Bertram T, Rogowski WH, Marckmann G. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics. 2013;14:55. https://doi.org/10.1186/1472-6939-14-55
Markus HS. Stroke genetics: prospects for personalized medicine. BMC Med. 2012;10:113. https://doi.org/10.1186/1741-7015-10-113
O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusoff K, Truelsen T, Diener HC, Sacco RL, Ryglewicz D, Czlonkowska A, Weimar C, Wang X, Yusuf S. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112-123. https://doi.org/10.1016/S0140-6736(10)60834-3
Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160-2236. https://doi.org/10.1161/STR.0000000000000024
Kim J, Thrift AG, Nelson MR, Bladin CF, Cadilhac DA. Personalized medicine and stroke prevention: where are we? Vasc Health Risk Manag. 2015;11:601-611. https://doi.org/10.2147/VHRM.S77571
Zuern CS, Lindemann S, Gawaz M. Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management. Semin Thromb Hemost. 2009;35(3):295-306. https://doi.org/10.1055/s-0029-1222608
Maksimova MYu, Sazonova VYu, Airapetova AS. Gendernye osobennosti narushenii mozgovogo krovoobrashcheniya v razlichnykh vozrastnykh gruppakh. Annaly klinicheskoi i ehksperimental’noi nevrologii. 2019;13(3):11-19. (In Russ.).
Smith EE, Saposnik G, Biessels GJ, Doubal FN, Fornage M, Gorelick PB, Seshadri S. Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2016;48(2):44-71. https://doi.org/10.1161/STR.0000000000000116
Filis K, Toufektzian L, Galyfos G, Sigala F, Kourkoveli P, Georgopoulos S, Vavuranakis M, Vrachatis D, Zografos G. Assessment of the vulnerable carotid atherosclerotic plaque using contrastenhanced ultrasonography. Vascular. 2017;25(3):316-325. https://doi.org/10.1177/1708538116665734
Gulevskaya TS, Morgunov VA, Anufriev PL. Struktura ateroskleroticheskih blyashek karotidnogo sinusa i narusheniya mozgovogo krovoobrashcheniya. Annals of Clinical and Experimental Neurology. 2010;4(1):13-19. Accessed January 4, 2021. (In Russ.). https://cyberleninka.ru/article/n/struktura-ateroskleroticheskih-blyashek-karotidnogo-sinusa-i-narusheniya-mozgovogo-krovoobrascheniya
Evdokimenko AN, Chechetkin AO, Druina LD, Tanashyan MM. Otsenka neovaskulyarizatsii ateroskleroticheskoi blyashki karotidnogo sinusa s pomoshch’yu kontrast-usilennogo UZI. Vestnik Rossiiskogo gosudarstvennogo meditsinskogo universiteta. 2019;4:25-33. (In Russ.). https://doi.org/10.24075/vrgmu.2019.057
Varetto G, Gibello L, Castagno C, Quaglino S, Ripepi M, Benintende E, Gattuso A, Garneri P, Zan S, Capaldi G, Bertoldo U, Rispoli P. Use of Contrast Enhanced Ultrasound in Carotid Atherosclerotic Disease: Limits and Perspectives. Biomed Res Int. 2015;2015:293163. https://doi.org/10.1155/2015/293163
Tanashyan MM, Raskurazhev AA, Shabalina AA, Lagoda OV, Gnedovskaya EV. Biomarkery tserebral’nogo ateroskleroza: vozmozhnosti rannei diagnostiki I prognozirovaniya individual’nogo riska. Annaly klinicheskoi i ehksperimental’noi nevrologii. 2015;9(3):20-25. Accessed January 4, 2021. (In Russ.).
Tanashyan MM, Ionova VG, Orlov SV, Omel’chenko NG, Shabalina AA, Kostyreva MV. Hronicheskie cerebrovaskulyarnye zabolevaniya, metabolicheskij sindrom i sostoyanie sistem gemoreologii i gemostaza. Terapevticheskij arhiv. 2010;82(10):19-24. (In Russ.).
Liu L, Gao YH, Cao J, Zhang HX, Fan L, Hu GL, Hu YX, Li XL, Zou X, Li JH. High prevalence of aspirin resistance in elderly patients with cardiovascular disease and metabolic syndrome. J Geriatr Cardiol. 2016;13(6):531-536. https://doi.org/10.11909/j.issn.1671-5411.2016.06.009
Grandl G, Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Semin Immunopathol. 2018;40(2):215-224. https://doi.org/10.1007/s00281-017-0666-5
Piradov MA, Illarioshkin SN, Tanashyan MM. Nevrologiya XXI veka: diagnosticheskie, lechebnye i issledovatel’skie tekhnologii. Rukovodstvo dlya vrachej. V 3 tomah. M.: OOO ATMO; 2015. (In Russ.).
Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med. 1978;89:157-161. https://doi.org/10.7326/0003-4819-89-2-157
Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol. 1981;139:47-51. https://doi.org/10.1016/0002-9378(81)90410-5
Maksimova MYu, Chechetkin AO, Moskvicheva AS, Shabalina AA. Aterotromboticheskii insul’t u zhenshchin: trombogennyi potentsial krovi i sosudistaya stenka. Annaly klinicheskoi i ehksperimental’noi nevrologii. 2020;14(1):25-32. (In Russ.).
Meyer DM, Eastwood JA, Compton MP, Gylys K, Zivin JA, Ovbiagele B. Sex differences in antiplatelet response in ischemic stroke. Womens Health (Lond). 2011;7(4):465-474. https://doi.org/10.2217/WHE.11.45
Bellemain-Appaix A. Traitement antiagrégant plaquettaire chez la femme: une spécificité liée au sexe? Annales de Cardiologie et d’Angéiologie. 2016;65(6):395-403. https://doi.org/10.1016/j.ancard.2016.10.008
Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Wong KSL. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. New England Journal of Medicine. 2016;375(1):35-43. https://doi.org/10.1056/NEJMoa1603060
Schwartz KA. Aspirin resistance: a clinical review focused on the most common cause, noncompliance. The Neurohospitalist. 2011;1(2):94-103. https://doi.org/10.1177/1941875210395776
Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373:1849-1860. https://doi.org/10.1016/S0140-6736(09)60503-1
Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106:388-391. https://doi.org/10.1161/01.CIR.0000020190.45892.75
Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164:836-845. https://doi.org/10.7326/M16-0577
Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, Creager MA, Eckel RH, Elkind MS, Fornage M, Goldstein LB, Greenberg SM, Horvath SE, Iadecola C, Jauch EC, Moore WS, Wilson JA; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the Primary Prevention of Stroke A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014;45:3754-3832. https://doi.org/10.1161/STR.0000000000000046
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Munoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:596-646. https://doi.org/10.1161/CIR.0000000000000678
Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164(12):826-835. https://doi.org/10.7326/M15-2112
Smith EE, Markus HS. New Treatment Approaches to Modify the Course of Cerebral Small Vessel Diseases. Stroke. 2020;51(1):38-46. https://doi.org/10.1161/STROKEAHA.119.024150
Dawson J, Broomfield N, Dani K, Dickie DA, Doney A, Forbes K, Houston G, Kean S, Lees K, McConnachie A, Muir KW, Quinn T, Struthers A, Walters M. Xanthine Oxidase Inhibition for the Improvement of Long-Term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack (XILO-FIST) — protocol for a randomised double blind placebo-controlled clinical trial. Eur Stroke J. 2018;3:281-290. https://doi.org/10.1177/2396987318771426
Lee SJ, Lee JS, Choi MH, Lee SE, Shin DH, Hong JM. Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique. BMC Neurol. 2017;17:169. https://doi.org/10.1186/s12883-017-0950-y
Xiong Z, Lu W, Zhu L, Zeng L, Shi C, Jing Z, Xiang Y, Li W, Tsang CK, Ruan Y, Huang L. Dl-3-n-Butylphthalide treatment enhances hemodynamics and ameliorates memory deficits in rats with chronic cerebral hypoperfusion. Front Aging Neurosci. 2017;9:238. https://doi.org/10.3389/fnagi.2017.00238
Pauls MM, Moynihan B, Barrick TR, Kruuse C, Madigan JB, Hainsworth AH, Isaacs JD. The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: a systematic review. J Cereb Blood Flow Metab. 2018;38:189-203. https://doi.org/10.1177/0271678X17747177
Richman IB, Owens DK. Aspirin for Primary Prevention. Medical Clinics of North America. 2017;101(4):713-724. https://doi.org/10.1016/j.mcna.2017.03.004
Caprio FZ, Sorond FA. Cerebrovascular Disease: Primary and Secondary Stroke Prevention. Med Clin North Am. 2019;103(2):295-308. https://doi.org/10.1016/j.mcna.2018.10.001
Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM). 10-Year ASCVD Risk Calculator with Coronary Artery Calcium. Accessed September 21, 2018. https://astrocharm.org/calculator-working